bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc Receives FDA Accelerated Approval for SKYSONA Call Transcript

Sep 19, 2022 / 12:00PM GMT
Release Date Price: $5.93 (-6.47%)
Operator

Good day, and welcome to the SKYSONA launch call. (Operator Instructions) As a reminder, this call may be recorded.

I would now like to turn the call over to Courtney O'Leary, Investor Relations. You may begin.

Courtney O;Leary
bluebird bio, Inc. - IR Officer

' -

Good morning, everyone, and thank you for joining today's presentation. My name is Courtney O'Leary, Senior Manager of Investor Relations at bluebird bio. Before I begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including statements of the company's plans, expectations and intentions regarding our commercialization plans following the FDA approval of SKYSONA. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results.

A description of these risks is contained in our filings with the SEC,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot